Telix Pharmaceuticals


AU$275.3m market cap

AU$1.52 last close

Telix Pharmaceuticals is a Melbourne-headquartered global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly targeted radiation.

Investment summary

Telix is developing diagnostic and therapeutic radiopharmaceuticals for kidney, prostate and brain cancers. It acquired full global rights to the investigational TLX591-CDx prostate cancer imaging kit in December. It is commercialising TLX591-CDx (illumet) in the US and Europe, and anticipates filing for FDA approval in 2019 (pre-NDA meeting request submitted). Telix expects to fully enroll the ZIRCON Phase III for kidney cancer imaging agent TLX250-CDx by end 2019/early 2020. Preliminary data from the IPAX-1 Phase I/II study of TLX101 therapy in brain cancer are expected in Q319. Telix plans to progress TLX591 therapy into Phase III in chemo-naive prostate cancer in Q319. Two TLX250/I-O combo studies in kidney cancer are planned for mid-2019.

Y/E Dec
Revenue (A$m)
PBT (A$m)
EPS (c)
P/E (x)
P/CF (x)
2017A 0.4 (6.4) (6.4) (4.98) N/A N/A
2018A 10.3 (17.5) (15.7) (6.84) N/A N/A
2019E 9.4 (20.0) (24.1) (11.02) N/A N/A
2020E 9.4 (19.2) (23.5) (10.78) N/A N/A
Industry outlook

Big pharma has shown keen interest in MTR products. In 2017 Novartis acquired Advanced Accelerator Applications, the developer of the MTR therapeutic Lutathera, for US$3.9bn. In 2014 Bayer acquired Algeta for ~US$2.6bn; Algeta had developed Xofigo, a therapeutic radiopharmaceutical for prostate cancer. In December Novartis acquired prostate cancer radiopharmaceutical developer Endocyte for US$2.1bn.

Last updated on 25/07/2019
Share price graph
Balance sheet
Forecast net cash (A$m) 1.3
Forecast gearing ratio (%) N/A
Price performance
Actual 25.2 71.2 122.8
Relative* 22.2 60.5 104.7
52-week high/low A$1.7/A$0.6
*% relative to local index
Key management
Christian Behrenbruch CEO
Douglas Cubbin CFO